Matrixyl 3000

Matrixyl 3000 is a commercial matrikine peptide blend developed by Sederma (now a Croda brand) comprising two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). Both peptides carry a C16 palmitic acid chain that increases lipophilicity and facilitates penetration across the stratum corneum.

Palmitoyl tripeptide-1 contains the glycine-histidine-lysine (GHK) sequence derived from the alpha-2 chain of collagen I. Fibroblast surface receptors recognize this tripeptide as a collagen proteolysis fragment, triggering a matrikine tissue-repair signal via the TGF-beta pathway that upregulates synthesis of collagen I, collagen III, fibronectin, elastin, and glycosaminoglycans. In vitro collagen stimulation has been demonstrated at concentrations as low as 0.5 µM in human fibroblast models.

Palmitoyl tetrapeptide-7 corresponds to the GQPR sequence at positions 341-344 of the human IgG heavy chain. Its principal action is suppression of excess interleukin-6 (IL-6) secretion from keratinocytes. Chronic IL-6 elevation in aged and UV-irradiated skin upregulates matrix metalloproteinases (MMPs), which degrade collagen and elastin. In vitro research has reported up to 86% reduction in UV-induced interleukin production, suggesting the peptide protects existing extracellular matrix from inflammatory MMP-mediated breakdown by addressing a root upstream signal rather than directly inhibiting MMPs.

The two peptides are theoretically complementary: one stimulates new matrix deposition while the other reduces inflammatory matrix degradation.

The majority of available clinical data for Matrixyl 3000 originates from Sederma's proprietary testing. The manufacturer's most-cited study reported a 45% reduction in the surface area occupied by deep wrinkles and approximately 20% improvement in skin tonicity after two months of twice-daily topical application, measured by silicon-replica profilometry. The sample size, randomization status, and full study design have not been published in an independent peer-reviewed journal, limiting independent verification.

Li et al. (2023, Journal of Cosmetic Dermatology, vol. 22, pp. 3340-3346; PMID 37335808; DOI 10.1111/jocd.15849) conducted a 28-day open-label clinical evaluation of a multi-peptide eye serum formulated at 4% Matrixyl 3000 in 32 female subjects (mean age 28.5 years, range 20-45). Corneometry, elastometry, and PRIMOS profilometry of the crow's feet area recorded a 31.8% decrease in wrinkle count by day 14 and 33.3% by day 28, with significant improvements in stratum corneum hydration and skin elasticity. No adverse reactions were observed. The absence of a control arm and the young mean subject age limit generalizability to the broader aging population.

Schagen (2017, Cosmetics 4(2):16; DOI 10.3390/cosmetics4020016), a narrative review, summarized in vitro and clinical data for the component peptides, noting that palmitoyl tripeptide-1 stimulates collagen and glycosaminoglycan synthesis without the irritation profile associated with retinoids, and that palmitoyl tetrapeptide-7 inhibits constitutive and UVB-induced IL-6 production in keratinocytes. One reported in vivo study cited in the review found a 2.4% increase in collagen fiber density after three months of topical application of a palmitoyl peptide complex.

Overall, published human evidence is limited to modest sample sizes (n=20-40), short durations (4-8 weeks), and predominantly open-label or manufacturer-sponsored designs. Independent placebo-controlled trials specifically testing the Matrixyl 3000 blend are scarce in the peer-reviewed literature.

Typical dosage: Topical formulation (daily).

Matrixyl 3000 is supplied as a liquid ingredient solution (INCI: Glycerin (and) Water (and) Butylene Glycol (and) Carbomer (and) Polysorbate 20 (and) Palmitoyl Tripeptide-1 (and) Palmitoyl Tetrapeptide-7). Croda's technical documentation specifies an in-formula use level of 3-4% of the ingredient solution by weight. This translates to active peptide concentrations typically below 10 ppm in the final cosmetic product, a figure consistent with the Cosmetic Ingredient Review (CIR) Expert Panel's safety findings for these ingredients.

The Sederma efficacy study employed 3% of the ingredient solution in a topical serum applied twice daily (morning and evening) for two months. Li et al. (2023) used a serum formulated at 4% Matrixyl 3000 applied twice daily for 28 days. Some commercial and community formulations incorporate the ingredient at up to 8%, though no clinical data at these higher concentrations has been independently published.

Application frequency in published and manufacturer-referenced studies is twice daily, once in the morning and once in the evening. Meaningful anti-wrinkle effects in the cited data appeared after approximately 4-8 weeks of consistent twice-daily use.

Matrixyl 3000 is formulated exclusively for topical use in serums, moisturizers, and eye creams. It is not used as an injectable or systemic agent, and no oral dosing data exists.

This information is provided for educational reference only and does not constitute medical or dermatological advice. Formulation decisions should be guided by qualified cosmetic chemists and use guided by individual skin tolerance.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

In commercial products and community skincare practice, Matrixyl 3000 is incorporated alongside several other actives. Unless otherwise stated, all combinations described below are based on formulator practice and community use rather than controlled clinical trials; evidence for these combinations is anecdotal.

• Hyaluronic acid: the most common commercial pairing, providing concurrent hydration alongside structural matrix repair. Some in vitro data suggests hyaluronic acid may act as a penetration enhancer for certain actives, though this has not been clinically confirmed for Matrixyl 3000 specifically (anecdotal).

• Vitamin C (L-ascorbic acid): combined for complementary antioxidant and skin-brightening effects alongside peptide-mediated collagen stimulation. Compatibility requires pH management to stabilize ascorbic acid (anecdotal).

• Niacinamide: considered chemically compatible with peptide formulations; provides complementary skin barrier reinforcement and sebum regulation through different mechanisms (anecdotal).

• Retinol: sometimes used alongside Matrixyl 3000 for multi-pathway anti-aging approaches; Matrixyl 3000 is also presented as a retinoid alternative for individuals who cannot tolerate vitamin A derivatives, including during pregnancy. No head-to-head or combination clinical trials for this pairing have been published (anecdotal).

Matrixyl 3000 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Safe for topical use

The Cosmetic Ingredient Review (CIR) Expert Panel published a formal safety assessment in 2018 (Johnson W et al., International Journal of Toxicology; DOI 10.1177/1091581818807863) reviewing toxicological, irritation, sensitization, and genotoxicity data for palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. The panel concluded that these ingredients are safe as used in cosmetics in the present practices of use and concentration, noting that the very low use concentrations (typically below 10 ppm in the final product) and negative findings in key safety assays obviate toxicological concerns.

No clinically significant skin irritation, allergic contact sensitization, comedogenicity, or genotoxicity signals were identified in the reviewed safety dataset. In the Li et al. (2023) clinical study (n=32, 28 days, twice-daily application), no adverse reactions related to product use were observed.

No systemic toxicity concerns have been identified, consistent with the ingredient's topical-only application, high molecular weight of the palmitoyl conjugates relative to free peptides, and very low dermal absorption expected at cosmetic concentrations. The ingredient has no assigned ATC code or drug regulatory status in any major jurisdiction; it is classified and regulated as a cosmetic ingredient.

Matrixyl 3000 is widely cited as appropriate for sensitive skin and as an alternative topical active for populations in whom retinoids are contraindicated. No formal prospective safety data in pregnant or breastfeeding individuals has been published specifically for this blend. No known drug-drug interactions or systemic contraindications have been established. Standard patch testing prior to first use is advisable for individuals with a history of contact dermatitis or multiple cosmetic ingredient sensitivities.